Gastric intestinal metaplasia and tamoxifen: Can we reverse the inevitable?

Digestive Diseases and Sciences

Volumn 59, Issue 6, 2014, Pages 1078-1079

  Goldenring, James R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CERAMIDE; POLYPEPTIDE; SALAZOSULFAPYRIDINE; TAMOXIFEN;

BREAST CANCER; BREAST SURGERY; CANCER RISK; EDITORIAL; HELICOBACTER PYLORI; HUMAN; INFLAMMATORY CELL; INTESTINE METAPLASIA; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; SPASMOLYTIC POLYPEPTIDE EXPRESSING METAPLASIA; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS;

EPITHELIUM; FEMALE; HUMANS; METAPLASIA; STOMACH; TAMOXIFEN;

EID: 84902294531     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3088-4     Document Type: Editorial

References (11)

1. Moon CM, Kim SH, Lee SK et al. Chronic tamoxifen use is associated with a decreased risk of intestinal metaplasia in human gastric epithelium. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-013-2994-1.
2. Parsons AB, Lopez A, Givoni IE, et al. Exploring the mode-ofaction of bioactive compounds by chemical-genetic profiling in yeast. Cell. 2006;126:611-625. (Pubitemid 44163601)
3. Morad SA, Levin JC, Tan SF, et al. Novel off-target effect of tamoxifen-inhibition of acid ceramidase activity in cancer cells. Biochim Biophys Acta. 2013;1831:1657-1664.
4. Huh WJ, Khurana SS, Geahlen JH, et al. Tamoxifen induces rapid, reversible atrophy, and metaplasia in mouse stomach. Gastroenterology. 2012;142:21-24.
5. Goldenring JR, Nam KT, Wang TC, et al. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology. 2010;138(2207-10):2210.
6. Oshima H, Hioki K, Popivanova BK, et al. Prostaglandin E signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology. 2011;140:596-607.
7. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:672-682.
8. Kang JM, Kim N, Shin CM, et al. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication: a three-year follow-up study in Korea. Helicobacter. 2012;17:86-95.
9. Yoon H, Kim N, Lee HS, et al. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter. 2011;16:382-388.
10. de Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol. 2009;104:1342-1345.
11. Wada T, Ishimoto T, Seishima R, et al. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia. Cancer Sci. 2013;104:1323-1329.